

# Anthony M Mills

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5744622/publications.pdf>

Version: 2024-02-01

24  
papers

2,771  
citations

394286

19  
h-index

610775

24  
g-index

24  
all docs

24  
docs citations

24  
times ranked

2124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus <sup>1</sup> . <i>Clinical Infectious Diseases</i> , 2021, 72, e815-e824.	2.9	40
2	The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
3	Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 41-52.	1.8	3
4	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. <i>Lancet HIV</i> , 2020, 7, e16-e26.	2.1	53
5	A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , 2018, 32, 1431-1442.	1.0	72
6	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e211-e220.	2.1	108
7	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. <i>Lancet HIV</i> , 2017, 4, e195-e204.	2.1	64
8	Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. <i>Clinical Drug Investigation</i> , 2017, 37, 51-60.	1.1	5
9	Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF. <i>Patient</i> . 2015. 8. 359-371.	1.1	14
10	Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1 Infected Patients with HIV-1 RNA $\geq 100,000$ Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis. <i>AIDS Patient Care and STDs</i> , 2014, 28, 168-175.	1.1	27
11	Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. <i>Journal of Infectious Diseases</i> , 2014, 210, 354-362.	1.9	284
12	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2014, 14, 590-599.	4.6	87
13	A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> . 2014. 65. e118-e120.	0.9	97
14	Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate-Based Single-Tablet Regimens. <i>HIV Clinical Trials</i> , 2013, 14, 216-223.	2.0	61
15	Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naïve Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 164-170.	0.9	38
16	A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 96-100.	0.9	138
17	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. <i>Lancet</i> , 2012, 379, 2439-2448.	6.3	405
18	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. <i>Lancet</i> , 2011, 378, 238-246.	6.3	361

#	ARTICLE	IF	CITATIONS
19	The DUET trials: etravirine in the management of treatment-experienced HIV-1-infected patients. <i>HIV Therapy</i> , 2010, 4, 265-280.	0.6	1
20	Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals. <i>Current HIV Research</i> , 2010, 8, 564-576.	0.2	4
21	Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. <i>Antiviral Therapy</i> , 2010, 15, 1045-1052.	0.6	96
22	Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. <i>Aids</i> , 2009, 23, 1679-1688.	1.0	239
23	Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. <i>Aids</i> , 2007, 21, F1-F10.	1.0	62
24	Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2007, 370, 29-38.	6.3	477